Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)

  • End date
    Sep 30, 2023
  • participants needed
  • sponsor
    University of Rochester
Updated on 30 June 2022
platelet count
small molecule


The purpose of this study is to determine if using avatrombopag in patients with thrombocytopenia due to temozolomide treatment can safely improve a patient's platelet count and allow the patient to complete the temozolomide treatment course as planned.


The purpose of this study is to determine if using avatrombopag in patients with low platelet count due to temozolomide treatment is safe, while at the same time assess whether the avatrombopag can improve the low platelet count and allow the temozolomide treatment to continue as planned.

Condition Thrombocytopenia
Treatment Avatrombopag
Clinical Study IdentifierNCT04931849
SponsorUniversity of Rochester
Last Modified on30 June 2022


Yes No Not Sure

Inclusion Criteria

Histological confirmation of grade 2, 3 or 4 glioma
Subject has initiated concurrent RT and temozolomide followed by planned 6-12 cycles of temozolomide
Subject is willing and able to provide written informed consent
Subject is ≥ 18 years of age at the time of informed consent
Subject is willing and able to comply with all aspects of the protocol
Subject had platelet counts ≥ 100, 000/uL at the start of RT+TMZ or TMZ alone
Subject experienced grade ≥ 3 (moderate to severe) thrombocytopenia, defined by platelet counts ≤ 50 x 109/L, measured at least 24 hours apart, during the induction RT+TMZ, or at any time during the maintenance TMZ
Subject is able to continue to receive temozolomide regimen at the standard maintenance dose and schedule
Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Subject has a life expectancy > 12 weeks at screening and is able to receive at least 2 additional cycles of TMZ
Females of childbearing potential must agree to use a highly effective method of contraception (combination of condom, diaphragm, or sponge with a spermicide) throughout the entire study period and for 28 days after the investigational product (IP) discontinuation

Exclusion Criteria

History of hematologic malignancy, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic syndrome
Subject with history of solid tumor and has received chemotherapy alone or chemotherapy and radiation in the past 5 years
Subject has received > 2 previous lines of chemotherapy
Subjects who have previously received radiation treatments to the pelvic region including brachytherapy
Subject with an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit of normal (ULN) or total bilirubin ≥ 3 x upper limit of normal
Subject is known to be human immunodeficiency virus positive
Known clinically significant acute or active bleeding (e.g., gastrointestinal or central nervous system) within 7 days of screening
Known history of thrombophilia with high risk of thrombosis (e.g., homozygous factor V Leiden mutation or prothrombin G20210A mutation, anti-thrombin deficiency, protein C deficiency, protein S deficiency, or antiphospholipid antibody syndrome)
Subject has a medical condition that, in the opinion of the investigator, would compromise the subject's ability to safely complete the study, such as unstable angina, renal failure requiring dialysis, or active infection requiring intravenous antibiotics
History of arterial or venous thrombosis within 6 months of screening
Subject has used vitamin K antagonist within 7 days of screening (use of low molecular weight heparin, factor Xa inhibitors, or direct thrombin inhibitors is allowed)
Subject has a history of chronic platelet or bleeding disorder or thrombocytopenia due to another etiology other than temozolomide (e.g., chronic liver disease or immune thrombocytopenia purpura)
Subject has used moderate or strong dual inducer of cytochrome P450 (CYP) 2C9 or CYP3A4/5 such as rifampin within 7 days of screening, and/or moderate or strong dual inhibitor such as fluconazole
Subject has previously received a thrombopoietin receptor agonist (e.g., eltrombopag or romiplostim) for the treatment of temozolomide induced thrombocytopenia
Subject has received a platelet transfusion within 3 days of screening
Subject is unable to take oral medication
Female subjects who are lactating or pregnant at screening (as documented by positive serum beta-human chorionic gonadotropin [β-hCG] test) or the baseline visit (serum pregnancy test)
For all men and women of childbearing potential: Refusal or inability to use effective means of contraception
History of significant cardiovascular disease or arrhythmia known to increase the risk of thromboembolic events such as atrial fibrillation, coronary artery stent placement, angioplasty, or coronary artery bypass graft) within 6 months of screening
Subject is currently enrolled in another clinical study with any investigational drug or device within 30 days of screening; however, participation in observational studies is permitted
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note